TGF-β1: a novel target for cardiovascular pharmacology

Cytokine and Growth Factor Reviews

Volumn 18, Issue 3-4, 2007, Pages 279-286

  Redondo, Santiago ^a   Santos Gallego, Carlos G ^a   Tejerina, Teresa ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Cardiovascular; Cell communication; Cytokines; Growth factors; Signal transduction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; CYTOKINE; SIGNAL PEPTIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; DISEASE MARKER; DRUG MECHANISM; PRIORITY JOURNAL; RESTENOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR SYSTEM; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; STENOSIS, OCCLUSION AND OBSTRUCTION;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL COMMUNICATION; CONSTRICTION, PATHOLOGIC; CYTOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34250029517     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.04.005     Document Type: Short Survey

References (79)

1. Piek E., Heldin C.H., and Ten Dijke P. Specificity, diversity and regulation in TGF-beta superfamily signalling. FASEB J 13 (1999) 2105-2124
2. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 26 (2006) 1712-1720
3. Karsdal M.A., Larsen L., Engsig M.T., Lou H., Ferreras M., Lochter A., Delaisse J.M., and Foged N.T. Matrix metalloproteinase- dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277 (2002) 44061-44067
4. Yuan W., and Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 276 (2001) 38502-38510
5. Alexakis C., Mestries P., Garcia S., Petit E., Barbier V., Papy-Garcia D., Sagot M.A., Barritault D., Caruelle J.P., and Kern P. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1. FASEB J 18 (2005) 1147-1149
6. Shi Y., and Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-690
7. Yu W., Murray N.R., Weems C., Chen L., Guo H., Ethridge R., et al. Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J Biol Chem 278 (2003) 11167-11174
8. Grainger D.J. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24 (2004) 399-404
9. McCaffrey T.A., Du B., Fu C., Bray P.J., Sanborn T.A., Deutsch E., et al. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 31 (1999) 1627-1642
10. Di Guglielmo G.M., Le Roy C., Goodfellow A.F., and Wrana J.L. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5 (2003) 410-421
11. Ten Dijke P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29 (2004) 265-273
12. Redondo S., Ruiz E., Santos-Gallego C.G., Padilla E., and Tejerina T. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes 54 (2005) 811-817
13. Yagi K., Goto D., Hamamoto T., Takenoshita S., Kato M., and Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem 274 (1999) 703-709
14. Lebrin F., Deckers M., Bertolino P., and Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 15 (2005) 599-608
15. Lebrin F., Goumans M.J., Jonker L., Carvalho R.L., Valdimarsdottir G., Thorikay M., et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23 (2004) 4018-4028
16. Kamaraju A.K., and Roberts A.B. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem 280 (2005) 1024-1036
17. Seay U., Sedding D., Krick S., Hecker M., Seeger W., and Eickelberg O. TGF-{beta}-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J Pharmacol Exp Ther 315 (2005) 1005-1012
18. Bhowmick N.A., Ghiassi M., Aakre M., Brown K., Singh V., and Moses H.L. TGF- beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci USA 100 (2003) 15548-15553
19. 2+ influx involves the type III IP(3) receptor and regulates actin cytoskeleton. Am J Physiol Renal Physiol 282 (2002) F910-F920
20. Bakin A.V., Safina A., Rinehart C., Daroqui C., Darbary H., and Helfman D.M. A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell 15 (2004) 4682-4694
21. Besson A., Assoian R.K., and Roberts J.M. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?. Nat Rev Cancer 4 (2005) 948-955
22. Goodman L.V., and Majack R.A. Vascular smooth muscle cells express distinct transforming growth factor-beta receptor phenotypes as a function of cell density in culture. J Biol Chem 264 (1989) 5241-5244
23. Zhu S., Goldschmidt-Clermont P.J., and Dong C. Transforming growth factor- beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ Res 94 (2004) 617-625
24. Dong C., Li Z., Alvarez Jr. R., Feng X.H., and Goldschmidt-Clermont P.J. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 5 (2000) 27-34
25. Engel M.E., McDonnell M.A., Law B.K., and Moses H.L. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 274 (1999) 37413-37420
26. Mallat Z., and Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol 13 (2002) 523-529
27. Nillson J., Hansson G.K., and Shah P.K. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 25 (2005) 18-28
28. Cottrez F., and Groux H. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J Immunol 167 (2001) 773-838
29. Gorelik L., and Flavell R.A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12 2 (2000) 171-181
30. Marie J.C., Letterio J.J., Gavin M., and Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4 + CD25 + regulatory T cells. J Exp Med 201 (2005) 1061-1067
31. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., Merval R., Esposito B., Cohen J.L., Fisson S., Flavell R.A., Hansson G.K., Klatzmann D., Tedgui A., and Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12 2 (2006) 178-180
32. Grainger D.J., Kemp P.R., Metcalfe J.C., Liu A.C., Lawn R.M., Williams N.R., et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1 (1995) 174-179
33. O'Neil C.H., Boffa M.B., Hancock M.A., Pickering J.G., and Koschinsky M.L. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem 279 (2004) 55187-55195
34. Byrne C.D., Wareham N.J., Martensz N.D., Humphries S.E., Metcalfe J.C., and Grainger D.J. Increasde PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels. Atherosclerosis 140 (1998) 45-53
35. Kalinina N., Agrotis A., Antropova Y., Ilyinskaya O., Smirnov V., Tararak E., et al. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vasc Biol 224 (2004) 1391-1396
36. Topper J.N., Cai J., Qiu Y., Anderson K.R., Xu Y.Y., Deeds J.D., et al. Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci USA 19 (1997) 9314-9349
37. McCaffrey T.A., Du B.H., Consigli S., Szabo P., Bray P.J., Hartner L., et al. Genomic instability in the type II TGF-beta 1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 100 (1997) 2182-2228
38. Clark K.J., Cary N.R., Grace A.A., and Metcalfe J.C. Microsatellite mutation of type II transforming growth factor-beta receptor is rare in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 4 (2001) 555-559
39. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89 (2001) 930-940
40. Lutgens E., Gijbels M., Smook M., Heeringa P., Gotwals P., Koteliansky V.E., et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 22 (2002) 975-982
41. Negishi M., Lu D., Zhang Y.Q., Sawada Y., Sasaki T., Kayo T., et al. Upregulatory expression of furin and transforming growth factor-beta by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 21 (2001) 785-790
42. Leonarduzzi G., Sevanian A., Sottero B., Arkan M.C., Biasi F., Chiarpotto E., et al. Up-regulation of the fibrogenic cytokine TGF-beta1 by oxysterols: a mechanistic link between cholesterol and atherosclerosis. FASEB J 15 (2001) 1619-1621
43. Siegert A., Ritz E., Orth S., and Wagner J. Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-beta1 in vascular smooth muscle. J Mol Med 77 (1999) 437-445
44. Redondo S., Santos-Gallego C.G., Ganado P., Garcia M., Rico L., Del Rio M., et al. Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-beta. Circulation 107 (2003) 626-629
45. Cipollone F., Fazia M., Mincione G., Iezzi A., Pini B., Cuccurullo C., et al. Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 35 (2004) 2253-2257
46. Panutsopulos D., Papalambros E., Sigala F., Zafiropoulos A., Arvanitis D.L., and Spandidos D.A. Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions. Int J Mol Med 15 (2005) 603-610
47. Wang X.L., Liu S.X., and Wilcken D.E. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res 34 (1998) 404-410
48. Laviades C., Varo N., and Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 36 (2000) 517-522
49. Lijnen P.J., Petrov V.V., and Fagard R.H. Association between transforming growth factor-beta and hypertension. Am J Hypertens 16 (2003) 604-611
50. Chung I.M., Gold H.K., Schwartz S.M., Ikari Y., Reidy M.A., and Wight T.N. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 40 (2002) 2072-2081
51. Chamberlain J., Gunn J., Francis S.E., Holt C.M., Arnold N.D., Cumberland D.C., et al. TGF beta is active, and correlates with activators of TGF beta, following porcine coronary angioplasty. Cardiovasc Res 50 (2001) 125-136
52. Smith J.D., Bryant S.R., Couper L.L., Vary C.P., Gotwals P.J., Koteliansky V.E., et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 84 (1999) 1212-1222
53. Kingston P.A., Sinha S., David A., Castro M.G., Lowenstein P.R., and Heagerty A.M. Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta type II receptor inhibits luminal loss and constrictive remodelling after coronary angioplasty and enhances adventitial collagen deposition. Circulation 104 (2001) 2595-2601
54. Hristov M., and Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 8 (2004) 498-508
55. Henrich D., Hahn P., Wahl M., Wilhelm K., Dernbach E., Dimmeler S., et al. Serum derived from multiple trauma patients promotes the differentiation of endothelial progenitor cells in vitro: possible role of transforming growth factor-beta1 and vascular endothelial growth factor 165. Shock 21 (2004) 13-16
56. Fukuda D., Sata M., Tanaka K., and Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 111 (2005) 926-931
57. Sugiyama S., Kugiyama K., Nakamura S., Kataoka K., Aikawa M., Shimizu K., Koide S., Mitchell R.N., Ogawa H., and Libby P. Characterization of smooth muscle-like cells in circulating human peripheral blood. Atherosclerosis 187 (2006) 351-362
58. Ninomiya K., Takahashi A., Fujioka Y., Ishikawa Y., and Yokoyama M. Transforming growth factor-beta signaling enhances transdifferentiation of macrophages into smooth muscle-like cells. Hypertens Res 29 (2006) 269-276
59. Annes J.P., Munger J.S., and Rifkin D.B. Making sense of latent TGF beta activation. J Cell Sci 116 (2003) 217-224
60. Lindschau C., Quass P., Menne J., Guler F., Fiebeler A., Leitges M., et al. Glucose-induced TGF-beta1 and TGF-beta receptor-1 expression in vascular smooth muscle cells is mediated by protein kinase C-alpha. Hypertension 42 (2003) 335-341
61. Fernandez T., Amoroso S., Sharpe S., Jones G.M., Bliskovski V., Kovalchuk A., et al. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med 20 (2004) 1247-1255
62. Cambien F., Ricard S., Troesch A., Mallet C., Generenaz L., Evans A., et al. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28 (1996) 881-887
63. Yokota M., Ichihara S., Lin T.L., Nakashima N., and Yamada Y. Association of a T29 → C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101 (2002) 2783-2787
64. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 342 (2000) 1350-1358
65. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96 (2005) 612-616
66. Sheng H., Shao J., O'Mahony C.A., Lamps L., Albo D., Isakson P.C., et al. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene 18 (1999) 855-867
67. Yingling J.M., Blanchard K.L., and Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3 (2004) 1011-1022
68. Benigni A., Zoja C., Corna D., Zatelli C., Conti S., Campana M., et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14 (2003) 1816-1824
69. Mead A.L., Wong T.T., Cordeiro M.F., Anderson I.K., and Khaw P.T. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 44 (2003) 3394-3401
70. Grygielko E.T., Martin W.M., Tweed C.W., Thornton P.P., Harling J.D., Brooks D.P., et al. Inhibition of gene markers of fibrosis with a novel inhibitor of TGF{beta}-type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 313 (2005) 943-951
71. De Gouville A.C., Boullay V., Krysa G., Pilot J., Brusq J.M., Loriolle F., et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 145 (2005) 166-177
72. Bonniaud P., Margetts P.J., Kolb M., Schroeder J.A., Kapoun A.M., Damm D., et al. Progressive transforming growth factor {beta}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 171 (2005) 889-898
73. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62 (2002) 65-74
74. Matsuyama S., Iwadate M., Kondo M., Saitoh M., Hanyu A., Shimizu K., et al. SB-431542 and Gleevec inhibit transforming growth factor-beta- induced proliferation of human osteosarcoma cells. Cancer Res 63 (2003) 7791-7798
75. Jinnin M., Ihn H., and Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 69 (2006) 597-607
76. Porreca E., Di Febbo C., Baccante G., Di Nisio M., and Cuccurullo F. Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin. J Am Coll Cardiol 39 (2002) 1752-1757
77. Guo B., Koya D., Isono M., Sugimoto T., Kashiwagi A., and Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53 (2004) 200-208
78. Matsumoto Y., Uwatoku T., Oi K., Abe K., Hattori T., Morishige K., et al. Long-term inhibition of rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 181-186
79. Rumble J.R., Gilbert R.E., Cox A., Wu L., and Cooper M.E. Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy. J Hypertens 16 (1998) 1603-1609